President Trump’s comments on vaccines’ supposed link to autism and his proposed agency appointments are spurring scientists to take political action.

The Orphan Drug Act has opened the door to almost unlimited price tags for drugs to treat rare diseases — burdening insurers, government programs, and families for whom obtaining the medication is often a matter of life and death.

The system intended to help those with rare diseases is being manipulated by drugmakers to maximize profits and to protect niche markets for medicines that millions of people already take — and it’s all legal.

Tensions mount as Trump considers candidates for top health positions, a documentary highlights the overlap between autism and gender dysphoria, and ‘citation cartels’ are gaming the publication system.

If the ACA is repealed, it could mean loss of coverage for several surprising health provisions, including therapy for children with autism, breast-feeding support for working mothers and assistance with emergency room visits.

A merger between nonprofit California Integrated Data Exchange and the Inland Empire Health Information Exchange could lead to the pooling of medical records of 16.7 million people in California.

Don’t let Robert F. Kennedy Jr.’s appointment distract us from fighting the policy changes that could have dire consequences for people with autism.

The jury is still out on autism screening, technology to track wandering children is under attack, and a sensitive Santa Claus sees children on the spectrum.

The new director of the National Institute of Mental Health says work on brain circuits may yield treatments for autism.

Autism researchers in the United Kingdom fear that the country’s exit from the European Union will cut funding, scare away talent and strain partnerships.